BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37296184)

  • 21. Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Ono T; Toki S; Kobayashi E; Arakawa A; Sugiyama M; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Oct; 33(4):1311-1320. PubMed ID: 32715445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.
    Masola V; Maran C; Tassone E; Zin A; Rosolen A; Onisto M
    BMC Cancer; 2009 Aug; 9():304. PubMed ID: 19715595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Berberine and palmatine inhibit the growth of human rhabdomyosarcoma cells.
    Shinji S; Nakamura S; Nihashi Y; Umezawa K; Takaya T
    Biosci Biotechnol Biochem; 2020 Jan; 84(1):63-75. PubMed ID: 31462179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.
    Zeng FY; Cui J; Liu L; Chen T
    Cancer Lett; 2009 Nov; 284(2):157-64. PubMed ID: 19442434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness.
    Poli E; Barbon V; Lucchetta S; Cattelan M; Santoro L; Zin A; Milano GM; Zanetti I; Bisogno G; Bonvini P
    Oncoimmunology; 2022; 11(1):2096349. PubMed ID: 35813575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
    Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
    Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma.
    Annavarapu SR; Cialfi S; Dominici C; Kokai GK; Uccini S; Ceccarelli S; McDowell HP; Helliwell TR
    Lab Invest; 2013 Oct; 93(10):1090-9. PubMed ID: 23999248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma.
    Beltrán D; Anderson ME; Bharathy N; Settelmeyer TP; Svalina MN; Bajwa Z; Shern JF; Gultekin SH; Cuellar MA; Yonekawa T; Keller C; Campbell KP
    Skelet Muscle; 2019 May; 9(1):11. PubMed ID: 31054580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma.
    Kikuchi K; Soundararajan A; Zarzabal LA; Weems CR; Nelon LD; Hampton ST; Michalek JE; Rubin BP; Fields AP; Keller C
    Oncogene; 2013 Jan; 32(3):286-95. PubMed ID: 22349825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different pattern of matrix metalloproteinases expression in alveolar versus embryonal rhabdomyosarcoma.
    Diomedi-Camassei F; Boldrini R; Ravà L; Donfrancesco A; Boglino C; Messina E; Dominici C; Callea F
    J Pediatr Surg; 2004 Nov; 39(11):1673-9. PubMed ID: 15547833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
    Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM
    Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
    Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
    Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
    Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
    Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
    Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
    Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.
    Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M
    Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells.
    Tsuchiya K; Hosoi H; Misawa-Furihata A; Houghton PJ; Sugimoto T
    Int J Oncol; 2007 Jul; 31(1):41-7. PubMed ID: 17549403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.